Taurine is a sulfur-containing amino acid abundant in the central nervous system, where it serves multiple neuroprotective functions including osmoregulation, calcium homeostasis, antioxidant defense, and modulation of neurotransmitter systems. This page examines the therapeutic potential of taurine supplementation in neurodegenerative diseases[1].
| Property | Value |
|---|---|
| Category | Neuroprotective Supplement |
| Chemical Name | 2-aminoethanesulfonic acid |
| Natural Sources | Meat, seafood, energy drinks |
| Brain Concentration | High (second most abundant amino acid) |
| Dosing | 1-6 g/day |
| Safety | FDA GRAS status |
Taurine (2-aminoethanesulfonic acid) is one of the most abundant amino acids in the human body, with particularly high concentrations in the brain, retina, and heart. Unlike most amino acids, taurine is not incorporated into proteins but exists free in tissues, where it performs diverse physiological functions essential for neuronal health[2].
Taurine acts as a calcium modulator in neurons through multiple mechanisms[3]:
Taurine provides neuroprotection through[4]:
As an organic osmolyte, taurine[5]:
Taurine influences multiple neurotransmitter systems[6]:
Taurine supplementation may benefit AD patients through multiple mechanisms[7]:
Clinical studies have shown reduced taurine levels in CSF of AD patients, suggesting potential benefit from supplementation.
In PD, taurine may protect dopaminergic neurons through[8]:
Animal models demonstrate improved behavioral outcomes in MPTP-induced Parkinsonism with taurine treatment.
Taurine shows promise in ALS through[9]:
Potential benefits include[10]:
While large-scale clinical trials are limited, preliminary studies show:
| Study | Finding |
|---|---|
| Elderly subjects | Improved cognitive function |
| PD patients | Reduced oxidative stress markers |
| ALS patients | Potential benefit with riluzole combination |
Multiple animal studies demonstrate[11]:
| Purpose | Dose | Notes |
|---|---|---|
| General neuroprotection | 1-3 g/day | Standard supplementation |
| Therapeutic protocols | Up to 6 g/day | Under medical supervision |
Taurine is generally well-tolerated[12]:
| Condition | Concern |
|---|---|
| Renal impairment | Reduced excretion |
| Pregnancy/lactation | Insufficient safety data |
| Bipolar disorder | Theoretical mood effects |
Taurine shows synergistic potential with:
| Combination | Benefit |
|---|---|
| CoQ10 | Enhanced mitochondrial protection |
| Vitamin D | Combined anti-inflammatory effects |
| Omega-3 fatty acids | Synergistic neuroprotection |
| Melatonin | Enhanced antioxidant effects |
| Caffeine | Modulation of adenosine receptors |
Current research focuses on:
Taurine supplementation represents a promising neuroprotective strategy with a favorable safety profile. While further large-scale clinical trials are needed, existing evidence from preclinical studies and preliminary human data supports its potential as an adjunctive therapy in neurodegenerative diseases. The multiple mechanisms of action—antioxidant, anti-inflammatory, calcium modulation, and neuroprotection—make taurine an attractive candidate for combination therapy approaches.
The study of Taurine Supplementation For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Wu JY, et al. Taurine as a neuromodulator. Adv Exp Med Biol. 2019;1155:33-44. PMID:31342452 ↩︎
El Idrissi A, et al. Taurine in health and disease. J Biomed Sci. 2014;21(1):67. PMID:25062952 ↩︎
Ripps H, Shen W. Review: taurine—a very essential amino acid. Mol Vis. 2012;18:2673-2686. PMID:23170060 ↩︎
Menzie J, et al. Therapeutic applications of taurine in aging and neurodegeneration. Amino Acids. 2014;46(1):23-35. PMID:23975199 ↩︎
Gao J, et al. Taurine protects against neurodegenerative diseases: involvement of oxidative stress and neuroinflammation. Brain Res Bull. 2018;137:265-270. PMID:29288282 ↩︎
Saransaari P, Oja SS. Taurine in neural disorders. Adv Exp Med Biol. 2017;975 Pt 1:33-44. PMID:28528403 ↩︎
Chen K, et al. Taurine and neurodegenerative disease: a potential therapeutic strategy. * Behav Brain Res*. 2019;376:112200. PMID:31454523 ↩︎
Sun M, et al. Taurine as a potential therapeutic agent for Alzheimer's disease: targeting oxidative stress and neuroinflammation. J Alzheimers Dis. 2020;77(3):1045-1057. PMID:32925123 ↩︎
El Idrissi A. Taurine supplementation in amyotrophic lateral sclerosis. Adv Exp Med Biol. 2019;1155:311-321. PMID:31375948 ↩︎
Tadros MG, et al. Taurine in Huntington's disease: therapeutic potential. Neurochem Res. 2022;47(8):2345-2357. PMID:35419712 ↩︎
Oja SS, Saransaari P. Taurine as a neuroprotective agent. Adv Neurobiol. 2023;31:207-230. PMID:36921947 ↩︎
Gaines J, et al. Safety evaluation of taurine. Food Chem Toxicol. 2021;156:112575. PMID:34384789 ↩︎